Manage your blood sugar and protect your liver health with Glucevia®

Clinical studies

Randomized, double blind, placebo controlled, cross over, acute study: Visen et al, 2009

7-week randomized, double blinded, placebo controlled, cross over study: Zulet et al, 2014

Efficacy studies: pre-clinical data

High fat diet model: Ibarra et al, 2011

Obesity model: Monto et al, 2014

Diabetic model: Gomez et al, 2015

Safety and toxicology

Glucevia® research programPUBLIS

HED

Fatty liver and steatosis

Wiernsperger, 2013

Steatosis is excessive fat accumulation in the form of triglycerides in the liver: > 5% of hepatocytes that contain lipid droplets

Prevalence rate of 30% in the general population

Could progress towards a more severe form with inflammation and fibrosis: Non-Alcoholic Steatohepatitis (NASH)

Nonalcoholic Fatty Liver Disease (NAFLD)

World Gastroenterology Organisation, 2012http://www.centre-hepato-biliaire.org

Animals: BKS (db/db) female mice (5 weeks of age)

Design 7 months administration of:

Control diet (n=10) Diet with Glucevia (0,7g/kg of diet) (n=10)

Variables: Metabolic blood parameters (glucose, insulin,

cholesterol, triglycerides) Histological analyses of liver NAFLD blood parameters

5

Glucevia® a natural solution

Protocol: diabetic model

Journal of Diabetes & Metabolism, 2015; Vol 4(Issue 6)

-54%

Glucevia® significantly reduces fatty liver tissue and improved markers of healthy liver in diabetic animals after 7 months

Results: diabetic model

Micrographs of H&E (high) or Oil red O (down) stained sections of livers from diabetic mice administered control or Glucevia

Glucevia® control

Journal of Diabetes & Metabolism, 2015; Vol 4(Issue 6)

Glucevia® a natural solution

Diabetic model

Insulin was significantly reduced after 7 months as well as the HOMA-IR parameter showing reduced insulin-resistance in diabetic animals after administration of Glucevia (p<0.05)

Control Glucevia®

Initial Fasting Blood Glucose (mg/dl) 202.17 ± 28.39 202.00 ±56.20

Final Fasting Blood Glucose (mg/dl) 791.25 ± 140.44 726.31 ± 127.63

Insulin (mU/L) 5.60 ± 0.82 4.39 ± 1.50*

HOMA-IR 9.55 ± 1.33 5.36 ± 2.53*

Total cholesterol (mg/dl) 143.63 ± 24.77 133.12 ± 36.43

HDL-C (mg/dl) 88.00 ± 21.07 88.81 ± 35.05

Triglycerides (mg/dl) 264.83 ± 49.35 162.72 ± 73.90*

Adiponectin (µg/ml) 10.67 ± 1.79 13.14 ± 0.06

* p < 0.05

Journal of Diabetes & Metabolism, 2015; Vol 4(Issue 6)

Results: diabetic model

Suggested mechanisms of action for Glucevia

Effect on the liver and mechanism of action

Key takeaways

The last pre-clinical study on Glucevia ® recently published in the Journal of Diabetes and Metabolism shows:

Glucevia ® helps manage blood sugar levels and protects liver health, thus addressing 2 main issues for people at risk of prediabetes and/or metabolic syndrome.

Due to its hepato-protective effect, Glucevia ® could be a new and effective natural solution for preventing steatosis and non-alcoholic fatty liver disease.

www.glucevia.com

www.naturex.com